A

Agios Pharmaceuticals
D

AGIO

37.055
USD
-0.69
(-1.82%)
مغلق
حجم التداول
0
الربح لكل سهم
-7
العائد الربحي
-
P/E
3
حجم السوق
2,152,951,749
أصول ذات صلة
C
CRSP
-0.360
(-0.64%)
55.970 USD
E
EDIT
-0.04500
(-1.78%)
2.48500 USD
N
NTLA
0.080
(0.70%)
11.460 USD
Q
QURE
-0.055
(-0.41%)
13.435 USD
R
RARE
-0.265
(-0.94%)
27.810 USD
S
SGMO
-0.05170
(-9.72%)
0.48030 USD
S
SRPT
1.740
(10.71%)
17.980 USD
المزيد
الأخبار المقالات

العنوان: Agios Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.